De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Medacta Group Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Medacta Group has been growing earnings at an average annual rate of 18.1%, while the Medical Equipment industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 14% per year. Medacta Group's return on equity is 16.3%, and it has net margins of 10.3%.
Belangrijke informatie
18.1%
Groei van de winst
20.5%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 11.1% |
| Inkomstengroei | 14.0% |
| Rendement op eigen vermogen | 16.3% |
| Nettomarge | 10.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate
Sep 06
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?
Aug 21Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
Aug 06Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable
Jun 20We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
May 01Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet
Apr 17Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Mar 29Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Feb 22Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around
Feb 07Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult
Dec 18Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Dec 04Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Nov 15Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)
Oct 30If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity
Oct 17Is Medacta Group (VTX:MOVE) Using Too Much Debt?
Sep 29Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)
Aug 11Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?
Jul 27Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital
Jul 03At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?
Apr 28Is Medacta Group (VTX:MOVE) A Risky Investment?
Apr 08Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?
Dec 25Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal
Dec 09Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?
Nov 09Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching
Sep 16The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence
Aug 20Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors
Jul 02Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?
May 28Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return
May 12These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well
Mar 31Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?
Mar 17Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future
Feb 07Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?
Dec 10Medacta Group (VTX:MOVE) Knows How To Allocate Capital
Nov 05Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly
Sep 30Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?
Aug 26Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital
Jul 20Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?
May 19We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt
Apr 05What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition
Mar 02Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?
Feb 02The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More
Jan 12
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture
Dec 21Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?
Dec 03Opbrengsten en kosten
Opbrengsten en kosten
Hoe Medacta Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 544 | 56 | 271 | 20 |
| 31 Mar 24 | 528 | 52 | 262 | 19 |
| 31 Dec 23 | 511 | 47 | 252 | 19 |
| 30 Sep 23 | 496 | 49 | 245 | 17 |
| 30 Jun 23 | 481 | 50 | 237 | 17 |
| 31 Mar 23 | 459 | 48 | 228 | 16 |
| 31 Dec 22 | 437 | 46 | 220 | 15 |
| 30 Sep 22 | 417 | 47 | 212 | 14 |
| 30 Jun 22 | 397 | 47 | 203 | 14 |
| 31 Mar 22 | 380 | 49 | 193 | 12 |
| 31 Dec 21 | 363 | 52 | 182 | 11 |
| 30 Sep 21 | 354 | 54 | 173 | 10 |
| 30 Jun 21 | 345 | 57 | 164 | 8 |
| 31 Mar 21 | 324 | 47 | 160 | 7 |
| 31 Dec 20 | 302 | 37 | 155 | 7 |
| 30 Sep 20 | 298 | 24 | 166 | 7 |
| 30 Jun 20 | 294 | 10 | 177 | 7 |
| 31 Mar 20 | 302 | 11 | 177 | 8 |
| 31 Dec 19 | 311 | 12 | 176 | 8 |
| 30 Sep 19 | 301 | 22 | 162 | 6 |
| 30 Jun 19 | 291 | 33 | 147 | 5 |
| 31 Mar 19 | 282 | 39 | 143 | 5 |
| 31 Dec 18 | 273 | 46 | 139 | 4 |
| 31 Dec 17 | 245 | 33 | 129 | 3 |
| 31 Dec 16 | 219 | 39 | 113 | 3 |
Kwaliteitswinsten: MOVE has high quality earnings.
Groeiende winstmarge: MOVE's current net profit margins (10.3%) are lower than last year (10.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MOVE's earnings have grown by 18.1% per year over the past 5 years.
Versnelling van de groei: MOVE's earnings growth over the past year (13%) is below its 5-year average (18.1% per year).
Winst versus industrie: MOVE earnings growth over the past year (13%) exceeded the Medical Equipment industry 2.9%.
Rendement op eigen vermogen
Hoge ROE: MOVE's Return on Equity (16.3%) is considered low.